A simple antagonist in acute opioid poisoning: naloxone
Magalini, S.I.; Scrascia, E.; de Francisci, G.
Minerva Anestesiologica 45(1-2): 71-75
1979
ISSN/ISBN: 0375-9393 PMID: 38415 Document Number: 148896
Document emailed within 1 workday
Related Documents
Drennan, I.R.; Orkin, A.M. 2016: OPIOID CRISIS. Prehospital naloxone administration for opioid-related emergencies Jems: a Journal of Emergency Medical Services 41(3): 36-39Spetea, M.; Asim, M.Faheem.; Noha, S.; Wolber, G.; Schmidhammer, H. 2013: Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening Current Pharmaceutical Design 19(42): 7362-7372
Sanchez-Ramos, J.R.; Senay, E.C. 1987: Ophthalmic naloxone elicits abstinence in opioid-dependent subjects British Journal of Addiction 82(3): 313-315
Rugstad, H.E. 1975: Naloxone, a new morphine antagonist with significant advantages Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 95(30): 1736-1738
Curcio, F.; Franco, T.; Topa, M.; Baldassarre, C. 2011: Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey European Review for Medical and Pharmacological Sciences 15(8): 871-874
Gillman, M.A.; Lichtigfeld, F.J. 1986: Analgesic actions of naloxone suggest the presence of a hyperalgesic opioid system South African Medical Journal 70(11): 650-651
Bigo, P.; Manno, E.; Matani, A.; Franco, I. 1983: Important side-effects of naloxone as an antagonist of neuroleptoanalgesia Minerva Anestesiologica 49(6): 389-391
Fjellner, B.; Hägermark, O. 1984: The influence of the opiate antagonist naloxone on experimental pruritus Acta Dermato-Venereologica 64(1): 73-75
Freye, E. 1975: High doses of fentanyl as the sole anaesthetic agent and naloxone as its antagonist Der Anaesthesist 24(4): 145-150
Crain, S.M.; Shen, K.F. 1992: After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition Journal of Pharmacology and Experimental Therapeutics 260(1): 182-186
Pałucha, A.; Brański, P.; Pilc, A. 2004: Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms Polish Journal of Pharmacology 56(6): 863-866
Buchner, L.H.; Cimino, J.A.; Raybin, H.W.; Stewart, B. 1972: Naloxone reversal of methadone poisoning New York State Journal of Medicine 72(18): 2305-2309
Hüttel, M.S.; Christensen, K.N. 1979: Naloxone as antidote in benzodiazepine poisoning Ugeskrift for Laeger 141(29): 1979-1981
Laxmi, N.A.; Vijayan, E. 1998: Effects of chronic systemic administration of opioid peptides, naloxone and N-acetyl beta-endorphin antiserum on gonadotropins and testicular functions in the rat Indian Journal of Experimental Biology 36(4): 361-366
Arakawa, K.; Akami, T.; Okamoto, M.; Akioka, K.; Nakai, I.; Oka, T.; Nagase, H. 1993: Immunosuppression by delta opioid receptor antagonist Transplantation Proceedings 25(1 Part 1): 738-740
Bae, E.A.; Johansson, J.H. 1976: Severe dextro propoxyphene poisoning treated with naloxone Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 96(12): 698-699
Kato, H. 2008: Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence Nihon Arukoru Yakubutsu Igakkai Zasshi 43(5): 697-704
Wire, W.S.; Pelton, J.T.; Kazmierski, W.; Hruby, V.J.; Burks, T.F.; Shook, J.E. 1987: Structure-activity analysis of five constrained somatostatin like peptides with opioid antagonist properties Proceedings of the Western Pharmacology Society 30: 237-241
Lemcke, P.K.; Sugg, E.; Malarchik, M.; Lui, G.; Serra, M.; Yamamura, H.I.; Hruby, V.J.; Shook, J.E.; Burks, T.F. 1987: N-terminal cyclization of a nonsulfated CCK analogue exhibits opioid antagonist activity in vitro Proceedings of the Western Pharmacology Society 30: 223-226
Bot, G.; Blake, A.D.; Li, S.; Reisine, T. 1998: Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist Journal of Pharmacology and Experimental Therapeutics 284(1): 283-290